Anti-RON antibodies

US8603478B2 · kind B2 · utility

Assignee

• AVEO Pharmaceuticals, Inc. · US

Inventors

• Kerry Whalen · Waltham, US
• Steve Bottega · Cambridge, US
• Andrea Boudrow · Peabody, US
• Lyne Breault · Brookline, US
• Ting Chen · Austin, US
• James Gifford · Somerville, US
• May Han · Brookline, US
• Jinwei Jiang · Sharon, US
• Lorena Lerner · Newton, US
• Qing Liu · Acton, US
• Kristan Meetze · Lexington, US
• Sylvie Vincent · Somerville, US
• Solly Weiler · Newton, US
• William M. Winston, Jr. · Marlborough, US
• Jeno Gyuris · Lincoln, US

Key dates

• Filing date: Jul 6, 2011
• Grant date: Dec 10, 2013
• Expiry date: Oct 18, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d' Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.